SCHEMBL14714660

SCHEMBL14714660

O=C(NC(C(=O)NO)C(=O)NCc1cncs1)c1ccc(-c2ccc(OCCO)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PARP15 Q460N3 1/20 0.41
PARP10 Q53GL7 1/20 0.41
PPARG P37231 1/20 0.39
HRH3 Q9Y5N1 4/20 0.38
ANPEP P15144 1/20 0.36
ROCK2 O75116 1/20 0.35
ACACB O00763 1/20 0.35
CTSL P07711 1/20 0.35
RAB9A P51151 1/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TSHR P16473 1/20 0.35
HDAC1 Q13547 2/20 0.35
KDM1A O60341 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14715049 0.83 PPARG (0.51) PPARGHRH3ANPEP
SCHEMBL14715042 0.83 LMNA (0.54) ROCK2LMNASMN1; SMN2
SCHEMBL14715222 0.83 PPARG (0.39) PPARGHRH3ANPEP
SCHEMBL14715195 0.82 TSHR (0.57) ROCK2LMNASMN1; SMN2TSHRHDAC1
SCHEMBL14715017 0.82 HPGD (0.55) RAB9ALMNASMN1; SMN2TSHR
SCHEMBL14714981 0.81 ANPEP (0.49) PPARGHRH3ANPEP
SCHEMBL14715281 0.81 HRH3 (0.42) PPARGHRH3ROCK2HDAC1KDM1A
SCHEMBL14714737 0.81 KLKB1 (0.51) ROCK2RAB9AHDAC1KDM1A
SCHEMBL14715185 0.80 HPGD (0.56) RAB9ALMNASMN1; SMN2TSHR
SCHEMBL14715050 0.80 NPC1 (0.41) PPARGHRH3RAB9ASMN1; SMN2HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2562155-B1 HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO LTD (JP) 2019-06-05 EP disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-9499477-B2 Hydroxamic acid derivative TOYAMA CHEMICAL CO., LTD. (JP) 2016-11-22 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-9073821-B2 Hydroxamic acid derivative TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-07-07 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE TOYAMA CHEMICAL CO., LTD. (JP) 2013-03-21 US disclosed
EP-2562155-A1 NOVEL HYDROXAMIC ACID DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225335-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 PARP15 2390/4885PARP10 2800/4885PPARG 972/4885
US-20130072677-A1 NOVEL HYDROXAMIC ACID DERIVATIVE LCT, AGXT, HDAC9 PARP15 2390/4885PARP10 2800/4885PPARG 972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.